Ocular Surface Disease
An Introduction to Ocular Surface Disease
Ocular surface disease is a prevalent condition, and with the increasing use of screens and monitors, this trend is likely to continue. Treatment options include artificial tears and gels, short courses of corticosteroids and prescription drugs cyclosporine 0.05% and lifitegrast 5%. Several devices have recently been introduced that help to relieve meibomian gland congestion and offer an alternative treatment.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
The 40th World Ophthalmology Congress (WOC2026) will take place at the Prague Congress Centre, Czech Republic, from June 26–29, 2026, bringing together ophthalmologists and eye care professionals from across the world
This week in ophthalmology: a new ranibizumab biosimilar approval, smartphone-based artificial intelligence (AI) for ocular surface malignancy detection, an update on corneal allogenic intrastromal ring segments in keratoconus, diabetic eye disease data from ADA 2026 and FDA designations for a potential neurotrophic keratitis therapy. Here are five stories to catch up on this week.
Lacripep has received US Food and Drug Administration (FDA) orphan drug and fast track designations for neurotrophic keratitis (NK), as TearSolutions begins dosing patients in a phase II clinical trial of the investigational topical therapy.1
Join us to read the latest news and abstract highlights from ASCRS 2026 The American Society of Cataract and Refractive Surgery Annual Meeting returned to Washington, D.C. from April 10–13, bringing together cataract, refractive, cornea and anterior segment specialists from around ...
At ASCRS 2026, Dr Morgan Micheletti (Berkeley Eye Center, Houston, Texas) presents findings from the JAMES study, exploring structural and optical changes across a range of commonly used IOL designs. In this Q&A, he discusses the study rationale, key observations and the implications for future device handling, storage and potential surgical use in spaceflight.
Conjunctival nevi are common benign lesions of the conjunctiva. Occasionally, they can transform into, or be confused with, aggressive malignancies such as melanomas. They can present at any age, including in children and adolescents. While usually asymptomatic, they can cause ...
Specializing in ophthalmology is an exciting milestone – but it can also feel overwhelming. The transition from training to independent practice comes with big decisions, new responsibilities and the pressure to build a career that will stand the test of time. We asked members of our faculty and Future Leaders what guidance they would offer to colleagues just beginning their careers.
Cloudbreak Pharma has announced positive topline results from its phase II trial of CBT‑004, a novel ophthalmic eye drop designed to treat vascularized pinguecula.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Taking place from 7–9 June 2025 in Lisbon, Portugal, the SOE Congress is one of Europe's leading multi-specialty ophthalmology meetings. With a world-class scientific programme, this in-person event offers a rich mix of symposia, live surgery, debates, workshops, mystery cases and updates ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dry eye disease (DED) is a prevalent ocular condition characterized by discomfort, visual disturbances and tear film instability due to insufficient tear production or rapid tear evaporation.1Â With an increasing global incidence (i.e. up to 50%) and its significant impact ...
Dry eye disease (DED) is a multifactorial condition of the ocular surface and tears. It is frequently encountered in ocular practices, comprising nearly 33% of visits in the USA, and with an estimated global prevalence ranging between 5% and 50%.1,2Â The chronic symptoms ...
Reproxalap is a reactive aldehyde species (RASP) inhibitor believed to mitigate inflammatory conditions such as dry eye disease (DED), allergic conjunctivitis and uveitis.1 RASP are pro-inflammatory molecules that covalently bind to thiol and amino groups expressed on various receptors and ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
